Japanese journal of infectious diseases最新文献

筛选
英文 中文
Genetic comparison of human parainfluenza virus type 3 detected in respiratory samples from patients with encephalopathy and airway inflammation in Aichi Prefecture, Japan 日本爱知县脑病和气道炎症患者呼吸道样本中检测到的人类副流感病毒 3 型的基因比较
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.265
Hirokazu Adachi, Hiroko Minagawa, Emi Hirose, Noriko Nakamura, Hitomi Niimi, Noriko Saito, Miyabi Ito, Katsuhiko Sato, Yoshihiro Yasui
{"title":"Genetic comparison of human parainfluenza virus type 3 detected in respiratory samples from patients with encephalopathy and airway inflammation in Aichi Prefecture, Japan","authors":"Hirokazu Adachi, Hiroko Minagawa, Emi Hirose, Noriko Nakamura, Hitomi Niimi, Noriko Saito, Miyabi Ito, Katsuhiko Sato, Yoshihiro Yasui","doi":"10.7883/yoken.jjid.2023.265","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.265","url":null,"abstract":"</p><p>Human parainfluenza virus type 3 (HPIV-3, Human respirovirus 3) is the second most frequently detected virus after human respiratory syncytial virus (HRSV) in lower respiratory tract infections in children. HPIV-3, like its close relative respiratory viruses, HRSV and influenza virus, may cause encephalopathy, but the relevance of HPIV-3 as a pathogenic factor in encephalopathy is unknown. We attempted to detect HPIV-1 through 4, HRSV, and human metapneumovirus (HMPV) in 136 patients with encephalitis/encephalopathy, or suspected encephalitis/encephalopathy during a 6-year period from 2014 to 2019. As a result, HPIV-3 was detected most frequently in 6 patients, followed by HRSV in 3. The HPIV-3 strains detected were closely related to those detected in a patient with respiratory disease at the same period. Although HPIV-3 is less recognized than HRSV as a triggering virus of encephalopathy, our results suggest that HPIV-3 is at least as important as HRSV. Surveillance of the causative virus of encephalopathy, including HPIV-3, would help to clarify the actual status of encephalopathy, the cause of which is currently reported in less than half of cases in Japan.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"217 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
β-Lactam Susceptibility of Streptococcus dysgalactiae subsp. equisimilis 对β-内酰胺类药物敏感的赤痢链球菌马氏亚种
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.339
Natsumi Nakashima, Wanchun Jin, Jun-ichi Wachino, Shinobu Koyama, Kiyoko Tamai, Yoshichika Arakawa, Kouji Kimura
{"title":"β-Lactam Susceptibility of Streptococcus dysgalactiae subsp. equisimilis","authors":"Natsumi Nakashima, Wanchun Jin, Jun-ichi Wachino, Shinobu Koyama, Kiyoko Tamai, Yoshichika Arakawa, Kouji Kimura","doi":"10.7883/yoken.jjid.2023.339","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.339","url":null,"abstract":"</p><p>All clinical isolates of <i>Streptococcus dysgalactiae </i>subsp. <i>equisimilis </i>(SDSE) are considered susceptible to β-lactams, the first-line drugs used for SDSE infections. However, penicillin-non-susceptible SDSE has been reported from Denmark. In this study, we attempted to detect β-lactam-non-susceptible clinical isolates of SDSE in Japan. One hundred and fifty clinical isolates of <i>S. dysgalactiae</i> were collected in 2018, and species identification was performed using Rapid ID Strep API. The minimum inhibitory concentrations (MIC) of six β-lactams (penicillin G, oxacillin, ceftizoxime, ceftibuten, cefoxitin, and cefaclor) were determined for 85 clinical isolates of SDSE using the agar dilution method standardized by the Clinical Laboratory Standards Institute. For the 85 isolates identified as SDSE, the MIC ranges of penicillin G, oxacillin, ceftizoxime, ceftibuten, cefoxitin, and cefaclor were 0.007–0.06, 0.03–0.12, 0.015–0.06, 0.25–2, 0.12–2, and 0.06–0.5 μg/mL, respectively. None of the clinical isolates were non-susceptible to penicillin G, indicating that all 85 clinical isolates of SDSE were susceptible to β-lactams. Our findings indicate that almost all clinical isolates of SDSE in several prefectures of Japan remain susceptible to β-lactams. Nevertheless, there remains a need for continuous and careful monitoring of drug susceptibility among clinical isolates of SDSE in Japan.<b> </b><b> </b></p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"167 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Efficacy and Safety of Nafamostat Mesylate in the Treatment of COVID-19: A Meta-Analysis 甲磺酸萘莫司他治疗 COVID-19 的有效性和安全性:元分析
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.315
Mian Wei, Toni Li, Siyuan Liu, Yushu Wang, Carolyn Tran, Guangyu Ao
{"title":"The Efficacy and Safety of Nafamostat Mesylate in the Treatment of COVID-19: A Meta-Analysis","authors":"Mian Wei, Toni Li, Siyuan Liu, Yushu Wang, Carolyn Tran, Guangyu Ao","doi":"10.7883/yoken.jjid.2023.315","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.315","url":null,"abstract":"</p><p>Nafamostat mesylate, a synthetic serine protease inhibitor, has demonstrated early antiviral activity against SARS-CoV-2 and anticoagulant properties that may be beneficial in COVID-19. We conducted a meta-analysis evaluating the efficacy and safety of nafamostat mesylate for COVID-19 treatment. PubMed, Embase, Cochrane Library, Scopus, Web of Science, medRxiv and bioRxiv were searched up to July 2023 for studies comparing outcomes between nafamostat mesylate treatment and no nafamostat mesylate treatment in COVID-19 patients. Mortality, disease progression and adverse events were analyzed. Six studies involving 16,195 patients were included. Meta-analysis revealed no significant difference in mortality (OR=0.88, 95%CI: 0.20-3.75, P=0.86) or disease progression (OR=2.76, 95%CI: 0.31-24.68, P=0.36) between groups. However, nafamostat mesylate was associated with increased hyperkalemia risk (OR=7.15, 95%CI: 2.66 to 19.24, P&lt;0.0001). Nafamostat mesylate does not improve mortality or morbidity in hospitalized COVID-19 patients compared to no nafamostat mesylate treatment. The significant hyperkalemia risk is a serious concern requiring monitoring and preventative measures. Further research is needed in different COVID-19 populations.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"19 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance patterns of common Gram-negative microorganisms isolated from patients with lower respiratory tract infection in a Teaching Hospital in Vietnam 越南一家教学医院下呼吸道感染患者中分离出的常见革兰氏阴性微生物的抗菌药耐药性模式
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.260
Hoang Huy Le, An Van Nguyen, Luong Huy Vu, Vinh Thi Ha Nguyen, Hoa Quynh Pham, Hung Van Le, Son Thai Nguyen, Hong Thu Le, Hung Viet Dinh, Nam Van Le, Tuan Dinh Le, Minh Nhat Le, Viet Hoang Nguyen, Kien Trung Hoang, Hai Ha Long Le
{"title":"Antimicrobial resistance patterns of common Gram-negative microorganisms isolated from patients with lower respiratory tract infection in a Teaching Hospital in Vietnam","authors":"Hoang Huy Le, An Van Nguyen, Luong Huy Vu, Vinh Thi Ha Nguyen, Hoa Quynh Pham, Hung Van Le, Son Thai Nguyen, Hong Thu Le, Hung Viet Dinh, Nam Van Le, Tuan Dinh Le, Minh Nhat Le, Viet Hoang Nguyen, Kien Trung Hoang, Hai Ha Long Le","doi":"10.7883/yoken.jjid.2023.260","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.260","url":null,"abstract":"</p><p>This cross-sectional study investigated the antimicrobial resistance (AMR) patterns of Gram-negative pathogens isolated from 4,789 hospitalized patients with lower respiratory tract infections (LRTIs). Of the collected specimens, 1,325 (27.7%) specimens tested positive for Gram-negative bacteria. The most prevalent isolates were <i>Acinetobacter baumannii</i> (38.6%), <i>Pseudomonas aeruginosa</i> (33.5%), <i>Klebsiella pneumoniae</i> (18.7%), <i>Escherichia coli</i> (5.6%), and <i>Klebsiella aerogenes</i> (3.5%). Antimicrobial resistance analysis revealed high resistance rates among <i>A. baumannii</i> isolates, showing resistance (79.9%-100%) to multiple classes of antibiotics, except amikacin, trimethoprim/sulfamethoxazole, and colistin. <i>P. aeruginosa</i> displayed lower resistance to colistin (&lt;10%), but resistance to other antibiotics was high. <i>K. pneumoniae </i>displayed elevated resistance rates against most penicillins, ranging from 90.0% to 100.0%. In contrast, the resistance rates were notably lower for colistin (7.1%) and amikacin (16.7%). <i>K. aerogenes</i> showed high resistance to various antibiotics, while sensitivity was observed for amikacin (95.1%), ampicillin (100.0%), and colistin (100.0%). <i>E. coli</i> exhibited resistance to ampicillin (96.9%) but showed maximum sensitivity to several antibiotics. The study identified significant antimicrobial resistance trends and highlighted the prevalence of multidrug-resistant strains (93.6% for <i>K. aerogenes</i> and 69.1%-92.4% for other isolates). These findings emphasize the urgent need for appropriate antibiotic stewardship practices to combat antimicrobial resistance in Gram-negative pathogens associated with LRTIs.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"64 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of cefiderocol, a novel siderophore cephalosporin, against multi-drug resistant Acinetobacter baumannii clinical isolates in Japan 新型嗜硒头孢菌素 cefiderocol 对日本耐多药鲍曼不动杆菌临床分离株的疗效
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.364
Yoshitaka Kimura, Nami Hatayama, Yoshinori Sato, Satoshi Nishida, Yusuke Yoshino
{"title":"Efficacy of cefiderocol, a novel siderophore cephalosporin, against multi-drug resistant Acinetobacter baumannii clinical isolates in Japan","authors":"Yoshitaka Kimura, Nami Hatayama, Yoshinori Sato, Satoshi Nishida, Yusuke Yoshino","doi":"10.7883/yoken.jjid.2023.364","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.364","url":null,"abstract":"</p><p>Multidrug-resistant <i>Acinetobacter baumannii</i> (MDRAB) is an important pathogen that causes nosocomial infections and is resistant to almost all antibiotics, including carbapenems. Cefiderocol is a novel siderophore cephalosporin that is active against a broad spectrum of Gram-negative bacteria. However, the susceptibility of MDRAB from Japan to cefiderocol has not yet been reported. In this study, we measured the minimum inhibitory concentrations (MICs) of antibiotics, including cefiderocol, against MDRAB clinical isolates collected during a nosocomial outbreak from 2009 to 2010 at Teikyo University Hospital in Japan. We found that all 10 MDRAB clinical isolates tested were susceptible to cefiderocol, with an MIC range of 0.12 to 1 μg/mL, all isolates were resistant to ampicillin-sulbactam, nine of the 10 isolates were susceptible to tigecycline, and all 10 isolates had an intermediate phenotype to colistin. DNA sequencing revealed that all strains harbored an OXA-51-like carbapenemase, one of the major causes of carbapenem resistance in <i>A. baumannii </i>in Japan. In conclusion, this study showed that susceptibility to cefiderocol of MDRAB clinical isolates in Japan was equivalent to that of colistin or tigecycline. Cefiderocol could be a possible choice for the treatment of MDRAB infections.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"8 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proton pump inhibitors and risk of bloodstream infection without an identifiable source: a hospital-based case-control study 质子泵抑制剂与无法确定来源的血流感染风险:一项基于医院的病例对照研究
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.253
Shintaro Hayashi, Tomohito Moriyama, Yuichiro Ito, Yuta Harada, Hiroki Dodo, Kana Kumahara, Tatsuji Yogi, Noritsugu Ohashi, Reiji Higashi, Akihiro Mori
{"title":"Proton pump inhibitors and risk of bloodstream infection without an identifiable source: a hospital-based case-control study","authors":"Shintaro Hayashi, Tomohito Moriyama, Yuichiro Ito, Yuta Harada, Hiroki Dodo, Kana Kumahara, Tatsuji Yogi, Noritsugu Ohashi, Reiji Higashi, Akihiro Mori","doi":"10.7883/yoken.jjid.2023.253","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.253","url":null,"abstract":"</p><p>The association between proton-pump inhibitor (PPI) use and systemic infections caused by bacterial translocation is unclear. This study aims to investigate whether patients receiving PPI therapy have a higher risk for bloodstream infections (BSI) without an identifiable source of infection, as an alternative indicator of BSI secondary to bacterial translocation. We conducted a hospital-based case–control study which enrolled all patients aged 20 years and older who developed BSI confirmed by two sets of positive blood culture and had inpatient care in Ichinomiya-Nishi Hospital in 2019. Patients’ data were collected from medical records, and bacterial translocation type (BT-type) BSI group were defined as those who had BSI without an identifiable source of infection, whereas the others were classified control group based on the diagnostic criteria for each infectious disease. We analyzed data from 309 patients, including 66 cases and 243 controls. PPI users had a 2.4-fold higher risk of developing BT-type BSI compared to non-PPI-users after controlling for potential confounders (OR: 2.41, 95% CI: 1.29–4.51<i>, p</i>=0.006). In conclusion, PPI use is associated with higher risk of BSI without an identifiable source and therefore, PPI use may increase the risk of septic morbidity secondary to bacterial translocation.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"27 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biofilm eradication of Stenotrophomonas maltophilia by Levofloxacin and Trimethoprim-sulfamethoxazole 左氧氟沙星和三甲氧苄氨嘧啶-磺胺甲噁唑对嗜麦芽糖单胞菌生物膜的根除作用
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-31 DOI: 10.7883/yoken.jjid.2023.389
José Mauricio Del Río-Chacón, Fabián Rojas-Larios, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Francisco Espinoza-Gómez, Adrián Camacho-Ortiz, Samantha Flores-Treviño
{"title":"Biofilm eradication of Stenotrophomonas maltophilia by Levofloxacin and Trimethoprim-sulfamethoxazole","authors":"José Mauricio Del Río-Chacón, Fabián Rojas-Larios, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Francisco Espinoza-Gómez, Adrián Camacho-Ortiz, Samantha Flores-Treviño","doi":"10.7883/yoken.jjid.2023.389","DOIUrl":"https://doi.org/10.7883/yoken.jjid.2023.389","url":null,"abstract":"</p><p><i>Stenotrophomonas maltophilia </i>is a non-fermenting Gram-negative drug-resistant pathogen causing healthcare-associated infections. Clinical isolates from Mexico were assessed for biofilm production by crystal violet staining. Antimicrobial susceptibility was evaluated using the broth microdilution method in planktonic and biofilm cells. The effect of antibiotics on the biofilm was visualized by fluorescence microscopy. Fifty isolates were included in the study, of which 28.0% were biofilm producers (64.2% from blood and 35.7% from respiratory samples). Resistance to levofloxacin (8.0%) and trimethoprim-sulfamethoxazole (44.0%) in planktonic cells increased to 100% in biofilm cells. Bacterial biofilm treated with several concentrations of both antibiotics was completely disrupted. In conclusion, <i>S. maltophilia</i> isolated from blood had higher biofilm production than those from respiratory samples. Resistance to antibiotics increased due to biofilm production. Antibiotic monotherapy might not be the best course of action for the treatment of <i>S. maltophilia </i>infections in Mexico, as they might also be causing biofilm production.</p>\u0000<p></p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":"7 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First Detection of Chimeric β-Lactamase CTX-M-64-Producing Salmonella Typhimurium from a Domestic Source in Japan. 日本首次检测到产嵌合型β-内酰胺酶 CTX-M-64 的鼠伤寒沙门氏菌。
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-24 Epub Date: 2023-08-31 DOI: 10.7883/yoken.JJID.2023.163
Tomu Kamijo, Kazuki Horiuchi, Tatsuya Negishi, Tatsuya Natori, Taku Yamane, Ayaka Hachiro, Takeshi Uehara, Wataru Hayashi, Noriyuki Nagano
{"title":"First Detection of Chimeric β-Lactamase CTX-M-64-Producing Salmonella Typhimurium from a Domestic Source in Japan.","authors":"Tomu Kamijo, Kazuki Horiuchi, Tatsuya Negishi, Tatsuya Natori, Taku Yamane, Ayaka Hachiro, Takeshi Uehara, Wataru Hayashi, Noriyuki Nagano","doi":"10.7883/yoken.JJID.2023.163","DOIUrl":"10.7883/yoken.JJID.2023.163","url":null,"abstract":"<p><p>Salmonella enterica subsp. enterica serovar Typhimurium has recently emerged worldwide as a producer of extended-spectrum β-lactamase (ESBL). However, drug-resistant clinical isolates are rare in Japan. The common types of ESBLs found are the CTX-M-type β-lactamases, including novel β-lactamases such as CTX-M-64. CTX-M-64 has a chimeric structure comprising a combination of the CTX-M-1 and CTX-M-9 groups. In 2017, S. Typhimurium was isolated from stool, blood, and urine cultures of an 82-year-old man. Herein, we describe the discovery of a clinical isolate of S. Typhimurium in Japan. Antimicrobial susceptibility testing revealed that the isolate was resistant to third- and fourth-generation cephalosporins, including ceftazidime and monobactam. The minimum inhibitory concentrations of ceftazidime and ceftriaxone were restored by administration of clavulanic acid. Whole-genome sequencing analysis revealed that the isolate harbored the bla<sub>CTX-M-64</sub> gene on an IncHI2/IncHI2A-type plasmid, with an assembly length of 174,477 bp. The genetic structure of the region surrounding the bla<sub>CTX-M-64</sub> gene, ISKpn26-ΔISEcp1-bla<sub>CTX-M-64</sub>-orf477, was shared only with the chromosome sequence of S. Typhimurium detected in food-producing chickens in Guangdong, China. Although rare, S. Typhimurium can induce bloodstream infections and produce ESBL. To our knowledge, this is the first report of a CTX-M-64-producing Enterobacterales clinical isolate of domestic origin in Japan.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":" ","pages":"47-50"},"PeriodicalIF":2.2,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10476431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
General Vaccination Readiness in Japan: Results from the JASTIS 2023 Study. 日本的总体疫苗接种准备情况:JASTIS 2023研究结果。
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-24 Epub Date: 2023-10-31 DOI: 10.7883/yoken.JJID.2023.261
Masaki Machida, Shigeru Inoue, Takahiro Tabuchi
{"title":"General Vaccination Readiness in Japan: Results from the JASTIS 2023 Study.","authors":"Masaki Machida, Shigeru Inoue, Takahiro Tabuchi","doi":"10.7883/yoken.JJID.2023.261","DOIUrl":"10.7883/yoken.JJID.2023.261","url":null,"abstract":"<p><p>General vaccine hesitancy is a global concern. Clarifying general vaccination readiness and the psychological factors comprising it is important. Previous studies reported that Japan has one of the lowest vaccine confidence levels worldwide. However, the status of other psychological factors comprising general vaccination readiness in Japan remains unclear. Therefore, we aimed to clarify the status of seven psychological factors comprising general vaccination readiness and their patterns in Japan. This descriptive study utilized data from a large-scale nationwide internet survey (Japan Society and New Tobacco Internet Survey 2023 study, N = 31,037). Seven psychological factors were assessed using the 7C of vaccination readiness scale. Cluster analysis was performed using k-means++ clustering to clarify patterns. Of the seven factors, support for social monitoring of people refusing vaccination (e.g., vaccine passports) was very low among the participants. Cluster analysis showed that the participants' vaccination readiness could be classified into six patterns, of which the very low vaccination readiness cluster, with the lowest scores for most psychological factors, accounted for 11.1% and was more common among those aged 30-49 years (13.1-16.4%). Individuals in this cluster may refuse to receive recommended vaccines.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":" ","pages":"34-39"},"PeriodicalIF":2.2,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71423604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Difference in the Dynamics of Antibody Titers between COVID-19 Vaccination and SARS-CoV-2 Infection in Healthcare Workers - A Case Study Based on Long-Term and Densely Repeated Measurements of Antibody Titers. 医护人员新冠肺炎疫苗接种和SARS-CoV-2感染之间抗体滴度动态的差异——基于抗体滴度长期密集测量的病例研究。
IF 2.2 4区 医学
Japanese journal of infectious diseases Pub Date : 2024-01-24 Epub Date: 2023-09-29 DOI: 10.7883/yoken.JJID.2023.175
Hirotaka Tanaka, Hiroyuki Sawatari, Shin-Ichi Ando
{"title":"Difference in the Dynamics of Antibody Titers between COVID-19 Vaccination and SARS-CoV-2 Infection in Healthcare Workers - A Case Study Based on Long-Term and Densely Repeated Measurements of Antibody Titers.","authors":"Hirotaka Tanaka, Hiroyuki Sawatari, Shin-Ichi Ando","doi":"10.7883/yoken.JJID.2023.175","DOIUrl":"10.7883/yoken.JJID.2023.175","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is prevalent worldwide, and effective and safe vaccines against this virus have been developed. Although trends in antibody titers after vaccination and/or SARS-CoV-2 infection have been reported, long-term studies with high frequency of measurements are limited. This report describes the long-term and detailed trends in the antibodies against SARS-CoV-2 S protein receptor-binding domain (S-RBD) measured repeatedly after vaccination and/or infection in 3 healthcare workers. All healthcare workers were administered 30 µg of the messenger RNA vaccine, BNT162b2, during all vaccinations. The peak value of the SARS-CoV-2 S-RBD titer was reached at 1-2 weeks after vaccination and then decreased by half within 8 weeks after vaccination; the peak values of the antibody titer increased with repeated vaccinations. In contrast, after SARS-CoV-2 infection, the peak value of the antibody titer was reached at 4-8 weeks after infection, and the antibody titer remained elevated up to 16-40 weeks after the peak. This report describes the long-term and detailed trends in the anti-SARS-CoV-2 S-RBD titers, showing different patterns after vaccination and/or SARS-CoV-2 infection.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":" ","pages":"51-54"},"PeriodicalIF":2.2,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信